Nektar Therapeutics expected to post a loss of $3.03 a share - Earnings Preview
Nektar Therapeutics
NKTR is expected to show a fall in quarterly revenue when it reports results on August 7 for the period ending June 30 2025The San Francisco California-based company is expected to report a 53.8% decrease in revenue to $10.849 million from $23.49 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Nektar Therapeutics is for a loss of $3.03 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Nektar Therapeutics is $95.00, about 75.5% above its last closing price of $23.27
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -2.39 | -2.46 | -3.60 | Missed | -46.1 |
Dec. 31 2025 | -2.71 | -2.52 | -2.40 | Beat | 4.9 |
Sep. 30 2024 | -3.34 | -3.16 | -2.70 | Beat | 14.6 |
Jun. 30 2024 | -3.08 | -3.05 | -3.75 | Missed | -22.8 |
Mar. 31 2024 | -2.88 | -2.85 | -2.85 | Met | 0 |
Dec. 31 2023 | -3.35 | -3.19 | -3.30 | Missed | -3.6 |
Sep. 30 2023 | -3.15 | -2.99 | -3.60 | Missed | -20.3 |
Jun. 30 2023 | -4.71 | -4.26 | -4.05 | Beat | 4.9 |
This summary was machine generated August 5 at 20:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
